SHR 1901
Alternative Names: SHR-1901Latest Information Update: 09 Feb 2022
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Jan 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (SC) (NCT05193721)
- 04 Jan 2022 Preclinical trials in Solid tumours in China (SC) before January 2022
- 27 Aug 2021 Shanghai Hengrui Pharmaceutical receives the approval and issuance of SHR 1901 injection by the State Drug Administration for clinical use